High-Load Core@Shell Nanocarriers with Irinotecan and 5-Fluorouracil for Combination Chemotherapy in Colorectal Cancer

被引:0
|
作者
Notter, Silke [1 ]
Choezom, Dolma [2 ,3 ,4 ]
Griebel, Titus [2 ,3 ]
Ramos-Gomes, Fernanda [3 ]
Moebius, Wiebke [3 ]
De Oliveira, Tiago [4 ]
Conradi, Lena-Christin [4 ]
Alves, Frauke [2 ,3 ,5 ]
Feldmann, Claus [1 ]
机构
[1] Karlsruhe Inst Technol KIT, Inst Inorgan Chem, Engesserstr 15, D-76131 Karlsruhe, Germany
[2] Univ Med Ctr Goettingen UMG, Clin Haematol & Med Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany
[3] Max Planck Inst Multidisciplinary Sci MPI NAT, Dept Neurogenet, City Campus,Hermann Rein Str 3, D-37075 Gottingen, Germany
[4] Univ Med Ctr Goettingen UMG, Dept Gen Visceral & Pediat Surg, Robert Koch Str 40, D-37075 Gottingen, Germany
[5] Univ Med Ctr Goettingen UMG, Inst Diagnost & Intervent Radiol, Robert Koch Str 40, D-37075 Gottingen, Germany
来源
SMALL SCIENCE | 2024年 / 4卷 / 11期
关键词
5-fluorouracil; colorectal cancer; drug delivery; irinotecan; tumor combination therapy; DRUG-DELIVERY; NANOPARTICLES; PACLITAXEL; PROGRESS; TRIAL;
D O I
10.1002/smsc.202400196
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Colorectal cancer (CRC) is the third most common cancer type and second leading cause of cancer-related deaths worldwide, requiring novel drug-delivery concepts. ITC@ZrO(TocP)/ZrO(FdUMP) core@shell nanocarriers (designated ITC-FdUMP-NC) with the clinically relevant chemotherapeutics irinotecan (ITC) and fluoro-2 '-deoxyuridine-5 '-phosphate (FdUMP) (active derivative of 5 '-fluorouracil/5-FU) are a new type of nanocarrier with high drug payload (22 wt% of lipophilic ITC: particle core; 10 wt% of hydrophilic FdUMP: particle shell). The nanocarriers are tested in different CRC cell lines, a normal cell line, and rectal cancer patient-derived organoids (PDOs). Fluorescence-labeled nanocarriers show efficient uptake by all CRC cells and allow to distinctly track the intracellular trafficking toward endolysosomal compartments. Although free chemotherapeutic drugs exhibit a greater potency in 2D cell cultures, ITC-FdUMP-NC demonstrate equivalent cytotoxic efficacies as the freely dissolved drugs in the more complex 3D rectal cancer PDOs. The sustained drug-release profile of the nanocarriers contrasts favorably with conventional free drugs, potentially enhancing the therapeutic outcome in vivo. With a chemotherapeutic cocktail comparable to the clinically applied FOLFIRI (ITC + 5-FU), the ITC-FdUMP-NC represent a novel type of nanocarrier with high anti-tumor effect and high drug payload, offering a promising strategy to circumvent chemoresistance and to improve therapy efficacy in vivo with less side effects. A clinically relevant drug cocktail of irinotecan (ITC) and 5-fluorouridine (5-FU) is combined in a single nanocarrier with high drug payload (32%). The nanocarriers show efficient uptake and high efficacy in different human colon cancer and human rectal cancer cell lines as well as rectal cancer patient-derived organoids, also allowing to elucidate the membrane-trafficking pathway.image (c) 2024 WILEY-VCH GmbH
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Polyaminoacid Based Core@shell Nanocarriers of 5-Fluorouracil: Synthesis, Properties and Theranostics Application
    Szczech, Marta
    Hinz, Alicja
    Lopuszynska, Natalia
    Bzowska, Monika
    Weglarz, Wladyslaw P.
    Szczepanowicz, Krzysztof
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [2] Cocktail of lipophilic and hydrophilic chemotherapeutics in high-load core@shell nanocarriers to treat pancreatic tumours
    Rudolph, David
    Ischyropoulou, Myrto
    Pfeifer, Juliana
    Napp, Joanna
    Schepers, Ute
    Alves, Frauke
    Feldmann, Claus
    NANOSCALE ADVANCES, 2024, 6 (03): : 973 - 984
  • [3] The advancing of polymeric core-shell ZnO nanocomposites containing 5-fluorouracil for improving anticancer activity in colorectal cancer
    Mohammadian, Samaneh
    Avan, Amir
    Khazaei, Majid
    Maghami, Parvaneh
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (02) : 899 - 911
  • [4] The advancing of polymeric core–shell ZnO nanocomposites containing 5-fluorouracil for improving anticancer activity in colorectal cancer
    Samaneh Mohammadian
    Amir Avan
    Majid Khazaei
    Parvaneh Maghami
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397 : 899 - 911
  • [5] Bio- and Hemo-Compatible Silk Fibroin PEGylated Nanocarriers for 5-Fluorouracil Chemotherapy in Colorectal Cancer: In Vitro Studies
    Hudita, Ariana
    Radu, Ionut Cristian
    Zaharia, Catalin
    Ion, Andreea Cristina
    Ginghina, Octav
    Galateanu, Bianca
    Marutescu, Luminita
    Grama, Florin
    Tsatsakis, Aristidis
    Gurevich, Leonid
    Costache, Marieta
    PHARMACEUTICS, 2021, 13 (05)
  • [6] Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study
    Ghiringhelli, Francois
    Guiu, Boris
    Chauffert, Bruno
    Ladoire, Sylvain
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (34) : 4278 - 4283
  • [7] Sirolimus,bevacizumab,5-Fluorouracil and irinotecan for advanced colorectal cancer:A pilot study
    Francois Ghiringhelli
    Boris Guiu
    Bruno Chauffert
    Sylvain Ladoire
    World Journal of Gastroenterology, 2009, 15 (34) : 4278 - 4283
  • [8] Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study
    Kwon, Hyuk-Chan
    Oh, Sung Yong
    Lee, Suee
    Kim, Sung-Hyun
    Kim, Hyo-Jin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (46) : 6231 - 6235
  • [9] Bevacizumab plus infusional 5-fluorouracil,leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy:A pilot study
    Hyuk-Chan Kwon
    Sung Yong Oh
    Suee Lee
    Sung-Hyun Kim
    Hyo-Jin Kim
    World Journal of Gastroenterology, 2007, (46) : 6231 - 6235
  • [10] Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer
    Fioravanti, Anna
    Canu, Bastianina
    Ali, Greta
    Orlandi, Paola
    Allegrini, Giacomo
    Di Desidero, Teresa
    Emrilenegger, Urban
    Fontanini, Gabriella
    Danesi, Romano
    Del Tacca, Mario
    Falcone, Alfredo
    Bocci, Guido
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 619 (1-3) : 8 - 14